Ivermectin and Nitazoxanide Combination Therapy for COVID-19

Clinical Trial ID NCT04360356

Rank	Title	Journal	Year	PubWeight™‹?›
1	Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.	Lancet	2020	18.32
2	A Novel Coronavirus from Patients with Pneumonia in China, 2019.	N Engl J Med	2020	7.78
3	A novel coronavirus outbreak of global health concern.	Lancet	2020	4.85
4	Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane.	J Virol	2007	2.18
5	Localization to the nucleolus is a common feature of coronavirus nucleoproteins, and the protein may disrupt host cell division.	J Virol	2001	1.32
6	Nitazoxanide: a first-in-class broad-spectrum antiviral agent.	Antiviral Res	2014	1.32
7	An AlphaScreen®-based assay for high-throughput screening for specific inhibitors of nuclear import.	J Biomol Screen	2011	0.88
8	Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import.	Sci Rep	2016	0.83
9	Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice.	Int Immunopharmacol	2012	0.82
10	Nucleocytoplasmic transport of nucleocapsid proteins of enveloped RNA viruses.	Front Microbiol	2015	0.77